Page 1825 - Williams Hematology ( PDFDrive )

1800 Part XI: Malignant Lymphoid Diseases Chapter 109: Macroglobulinemia 1801

123. Hunter ZR, Manning RJ, Hanzis C, et al: IgA and IgG hypogammaglobulinemia in 153. Treon SP, Kelliher A, Keele B, et al: Expression of serotherapy target antigens in Wal-
Waldenström’s macroglobulinemia. Haematologica 95:470, 2010. denström’s macroglobulinemia: Therapeutic applications and considerations. Semin
124. Stone MJ, Bogen SA: Evidence-based focused review of management of hyperviscosity Oncol 30:248, 2003.
syndrome. Blood 119:2205, 2012. 154. Treon SP, Agus DB, Link B, et al: CD20-Directed antibody-mediated immunotherapy
125. Menke MN, Treon SP: Hyperviscosity syndrome, in Clinical Malignant Hematology, induces responses and facilitates hematologic recovery in patients with Waldenström’s
edited by M Sekeres, M Kalaycio, B Bolwell, p 937. McGraw Hill, New York, 2007. macroglobulinemia. J Immunother 24:272, 2001.
126. Moulopoulos LA, Dimopoulos MA, Varma DG, et al: Waldenström macroglobuline- 155. Gertz MA, Rue M, Blood E, et al: Multicenter phase 2 trial of rituximab for Walden-
mia: MR imaging of the spine and CT of the abdomen and pelvis. Radiology 188:669, ström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study
1993. (E3A98). Leuk Lymphoma 45:2047, 2004.
127. Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to initiate ther- 156. Dimopoulos MA, Zervas C, Zomas A, et al: Treatment of Waldenström’s macroglobu-
apy in Waldenström’s macroglobulinemia: Consensus Panel Recommendations from linemia with rituximab. J Clin Oncol 20:2327, 2002.
the Second International Workshop on Waldenström’s macroglobulinemia. Semin 157. Treon SP, Emmanouilides C, Kimby E, et al: Extended rituximab therapy in Walden-
Oncol 30:116, 2003. ström’s Macroglobulinemia. Ann Oncol 16:132, 2005.
128. Dimopoulos MA, Kastritis E, Owen RG et al: Treatment recommendations for patients 158. Treon SP, Branagan AR, Hunter Z, et al: Paradoxical increases in serum IgM and vis-
with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consen- cosity levels following rituximab in Waldenström’s macroglobulinemia. Ann Oncol
sus. Blood 124:1404, 2014. 15:1481, 2004.
129. Kyle RA, Greipp PR, Gertz MA, et al: Waldenström’s macroglobulinaemia: A prospec- 159. Ghobrial IM, Fonseca R, Greipp PR, et al: Initial immunoglobulin M “flare” after ritux-
tive study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737, imab therapy in patients with Waldenström macroglobulinemia: An Eastern Coopera-
2000. tive Oncology Group Study. Cancer 101:2593, 2004.
130. Dimopoulos MA, Alexanian R: Waldenström’s macroglobulinemia. Blood 83:1452, 160. Dimopoulos MA, Anagnostopoulos A, Zervas C, et al: Predictive factors for response
1994. to rituximab in Waldenström’s macroglobulinemia. Clin Lymphoma 5:270, 2005.
131. Petrucci MT, Avvisati G, Tribalto M, et al: Waldenström’s macroglobulinaemia: Results 161. Treon SP, Hansen M, Branagan AR, et al: Polymorphisms in FcγRIIIA (CD16) receptor
of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 226:443, expression are associated with clinical responses to rituximab in Waldenström’s macro-
1989. globulinemia. J Clin Oncol 23:474, 2005.
132. Case DC Jr, Ervin TJ, Boyd MA, Redfield DL: Waldenström’s macroglobulinemia: 162. Dimopoulos MA, Anagnostopulos A, Kyrtsonis MC, et al: Treatment of relapsed
Long-term results with the M-2 protocol. Cancer Invest 9:1, 1991. or refractory Waldenström’s macroglobulinemia with bortezomib. Haematologica
133. Facon T, Brouillard M, Duhamel A, et al: Prognostic factors in Waldenström’s macro- 90:1655, 2005.
globulinemia: A report of 167 cases. J Clin Oncol 11:1553, 1993. 163. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in patients with untreated
134. Leblond V, Johnson S, Chevret S, et al: Results of a randomized trial of chlorambucil or relapsed Waldenström’s macroglobulinemia: A phase II study of the National Cancer
versus fludarabine for patients with Waldenström macroglobulinemia, marginal zone Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570, 2007.
lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 31:301, 2013. 164. Weber DM, Dimopoulos MA, Delasalle K, et al: 2-chlorodeoxyadenosine alone and in
135. Dimopoulos MA, Kantarjian H, Weber D, et al: Primary therapy of Waldenström’s mac- combination for previously untreated Waldenström’s macroglobulinemia. Semin Oncol
roglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 12:2694, 1994. 30:243, 2003.
136. Delannoy A, Ferrant A, Martiat P, et al: 2-Chlorodeoxyadenosine therapy in Walden- 165. Treon SP, Branagan AR, Ioakimidis L, et al: Long-term outcomes to fludarabine and
ström’s macroglobulinaemia. Nouv Rev Fr Hematol 36:317, 1994. rituximab in Waldenström’s macroglobulinemia. Blood 113:3673, 2009.
137. Fridrik MA, Jager G, Baldinger C, et al: First-line treatment of Waldenström’s disease 166. Tam CS, Wolf MM, Westerman D, et al: Fludarabine combination therapy is highly
with cladribine. Arbeitsgemeinschaft Medikamentose Tumortherapie. Ann Hematol effective in first-line and salvage treatment of patients with Waldenström’s macroglob-
74:7, 1997. ulinemia. Clin Lymphoma Myeloma 6:136, 2005.
138. Liu ES, Burian C, Miller WE, Saven A: Bolus administration of cladribine in the treat- 167. Hensel M, Villalobos M, Kornacker M, et al: Pentostatin/cyclophosphamide with or
ment of Waldenström macroglobulinaemia. Br J Haematol 103:690, 1998. without rituximab: An effective regimen for patients with Waldenström’s macroglobu-
139. Hellmann A, Lewandowski K, Zaucha JM, et al: Effect of a 2-hour infusion of 2-chloro- linemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 6:131, 2005.
deoxyadenosine in the treatment of refractory or previously untreated Waldenström’s 168. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al: Primary treatment of
macroglobulinemia. Eur J Haematol 63:35, 1999. Waldenström’s macroglobulinemia with dexamethasone, rituximab and cyclophos-
140. Betticher DC, Hsu Schmitz SF, Ratschiller D, et al: Cladribine (2-CDA) given as sub- phamide. J Clin Oncol 25:3344, 2007.
cutaneous bolus injections is active in pretreated Waldenström’s macroglobulinaemia. 169. Buske C, Hoster E, Dreyling MH, et al: The addition of rituximab to front-line therapy
Swiss Group for Clinical Cancer Research (SAKK). Br J Haematol 99:358, 1997. with CHOP (R-CHOP) results in a higher response rate and longer time to treatment
141. Dimopoulos MA, Weber D, Delasalle KB, et al: Treatment of Waldenström’s macro- failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of
globulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identifica- the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 23:153, 2009.
tion of prognostic factors. Ann Oncol 6:49, 1995. 170. Treon SP, Hunter Z, Branagan A: CHOP plus rituximab therapy in Waldenström’s mac-
142. Dimopoulos MA, O’Brien S, Kantarjian H, et al: Fludarabine therapy in Waldenström’s roglobulinemia. Clin Lymphoma Myeloma 5:273, 2005.
macroglobulinemia. Am J Med 95:49, 1993. 171. Ioakimidis L, Patterson CJ, Hunter ZR, et al: Comparative outcomes following CP-R,
143. Foran JM, Rohatiner AZ, Coiffier B, et al: Multicenter phase II study of fludarabine CVP-R and CHOP-R in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma
phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Wal- 9:62, 2009.
denström’s macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 17:546, 1999. 172. Rummel M, Niederle N, Maschmeyer G, et al: Bendamustine plus rituximab versus
144. Thalhammer-Scherrer R, Geissler K, Schwarzinger I, et al: Fludarabine therapy in CHOP plus rituximab as first-line treatment for patients with indolent and mantle-
Waldenström’s macroglobulinemia. Ann Hematol 79:556, 2000. cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
145. Dhodapkar MV, Jacobson JL, Gertz MA, et al: Prognostic factors and response to flu- Lancet 381:1203, 2013.
darabine therapy in patients with Waldenström macroglobulinemia: Results of United 173. Treon SP, Hanzis C, Tripsas C, et al: Bendamustine therapy in patients with relapsed or
States intergroup trial (Southwest Oncology Group S9003). Blood 98:41, 2001. refractory Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk 211:133,
146. Zinzani PL, Gherlinzoni F, Bendandi M, et al: Fludarabine treatment in resistant 2011.
Waldenström’s macroglobulinemia. Eur J Haematol 54:120, 1995. 174. Dimopoulos MA, Hamilos G, Efstathiou E, et al: Treatment of Waldenström’s mac-
147. Leblond V, Ben Othman T, Deconinck E, et al: Activity of fludarabine in previously roglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk
treated Waldenström’s macroglobulinemia: A report of 71 cases. Groupe Cooperatif Lymphoma 44:993, 2003.
Macroglobulinemie. J Clin Oncol 16:2060, 1998. 175. Tamburini J, Levy V, Chateilex C, et al: Fludarabine plus cyclophosphamide in Walden-
148. Dimopoulos MA, Weber DM, Kantarjian H, et al: 2-Chlorodeoxyadenosine therapy ström’s macroglobulinemia: Results in 49 patients. Leukemia 19:1831, 2005.
of patients with Waldenström macroglobulinemia previously treated with fludarabine. 176. Treon SP, Ioakimidis L, Soumerai JD, et al: Primary therapy of Waldenström’s macro-
Ann Oncol 5:288, 1994. globulinemia with bortezomib, dexamethasone and rituximab. J Clin Oncol 27:3830,
149. Lewandowski K, Halaburda K, Hellmann A: Fludarabine therapy in Waldenström’s 2009.
macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine. Leuk 177. Ghobrial IM, Matous J, Padmanabhan S, et al: Phase II trial of combination of borte-
Lymphoma 43:361, 2002. zomib and rituximab in relapsed and/or refractory Waldenström’s macroglobulinemia.
150. Popat U, Saliba R, Thandi R, et al: Impairment of filgrastim-induced stem cell mobili- Blood 112:832, 2008.
zation after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow 178. Agathocleous A, Rohatiner A, Rule S, et al: Weekly versus twice weekly bortezomib
Transplant 15:718, 2009. given in conjunction with rituximab in patients with recurrent follicular lymphoma,
151. Leleu XP, Manning R, Soumerai JD, et al: Increased incidence of transformation and mantle cell lymphoma, and Waldenström macroglobulinemia. Br J Haematol 151:346,
myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia 2010.
treated with nucleoside analogs. J Clin Oncol 27:250, 2009. 179. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al: Primary therapy of Walden-
152. Leleu X, Tamburini J, Roccaro A, et al: Balancing risk versus benefit in the treatment ström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone,
of Waldenström’s macroglobulinemia patients with nucleoside analogue based therapy. and rituximab (BDR): Long-term results of a phase 2 study of the European Myeloma
Clin Lymphoma Myeloma 9:71, 2009. Network (EMN). Blood 122:3276, 2013.

Kaushansky_chapter 109_p1785-1802.indd 1800 9/21/15 12:31 PM